Neuropace Financial Statements From 2010 to 2026

NPCE Stock

USD 15.44 0.03 0.19%

Neuropace's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Neuropace's valuation are provided below:

Gross Profit

72.8 M

Profit Margin

(0.25)

Market Capitalization

515.3 M

Enterprise Value Revenue

5.5494

Revenue

94.9 M

There are over one hundred nineteen available fundamental ratios for Neuropace, which can be analyzed over time and compared to other ratios. Investors should ensure to check all of Neuropace's last-minute performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of January 1, 2026, Market Cap is expected to decline to about 190.6 M. In addition to that, Enterprise Value is expected to decline to about 229.7 M

Neuropace Total Revenue

57.59 Million

Check Neuropace financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuropace's main balance sheet or income statement drivers, such as Interest Income of 1.5 M, Depreciation And Amortization of 1.4 M or Interest Expense of 7.1 M, as well as many indicators such as Price To Sales Ratio of 5.25, Dividend Yield of 0.0 or PTB Ratio of 42.71. Neuropace financial statements analysis is a perfect complement when working with Neuropace Valuation or Volatility modules.

Build AI portfolio with Neuropace Stock

Check out the analysis of Neuropace Correlation against competitors.

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.

Neuropace Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

96.6 M

94.6 M

50.8 M

Slightly volatile

Short and Long Term Debt Total

69.9 M

73.3 M

63.5 M

Slightly volatile

Other Current Liabilities

8.7 M

9.8 M

6.2 M

Slightly volatile

Total Current Liabilities

18.2 M

15.2 M

51.9 M

Slightly volatile

Other Liabilities

1.1 M

819.9 K

1.5 M

Slightly volatile

Property Plant And Equipment Net

8.3 M

12.9 M

3.8 M

Slightly volatile

Current Deferred Revenue

527.2 K

555 K

4.5 M

Slightly volatile

Net Debt

53.8 M

59.9 M

54.7 M

Slightly volatile

Accounts Payable

2 M

3 M

1.3 M

Slightly volatile

Cash

16.1 M

13.4 M

8.8 M

Slightly volatile

Non Current Assets Total

8.7 M

13.3 M

4 M

Slightly volatile

Non Currrent Assets Other

452.5 K

413 K

196.6 K

Slightly volatile

Other Assets

535.3 K

563.5 K

8.6 M

Pretty Stable

Cash And Short Term Investments

65.2 M

52.8 M

29.1 M

Slightly volatile

Net Receivables

9.9 M

12.9 M

7.4 M

Slightly volatile

Common Stock Shares Outstanding

21.7 M

29.1 M

15 M

Slightly volatile

Short Term Investments

49.1 M

39.3 M

20.3 M

Slightly volatile

Liabilities And Stockholders Equity

96.6 M

94.6 M

50.8 M

Slightly volatile

Non Current Liabilities Total

70.8 M

71.5 M

80 M

Very volatile

Inventory

10.4 M

13.4 M

8.7 M

Slightly volatile

Other Current Assets

2.4 M

1.7 M

Slightly volatile

Other Stockholder Equity

452.5 M

538.9 M

272.9 M

Slightly volatile

Total Liabilities

89 M

86.6 M

131.9 M

Slightly volatile

Property Plant And Equipment Gross

21.9 M

20.9 M

4.7 M

Slightly volatile

Short and Long Term Debt

1.7 M

1.8 M

40 M

Slightly volatile

Total Current Assets

87.9 M

81.3 M

46.9 M

Slightly volatile

Non Current Liabilities Other

165 K

315.1 K

114.8 K

Slightly volatile

Short Term Debt

1.8 M

1.9 M

39.9 M

Slightly volatile

Common Stock

20 K

30 K

8.6 K

Slightly volatile

Property Plant Equipment

822.8 K

1.2 M

837 K

Slightly volatile

Long Term Debt

59.4 M

59.5 M

52.4 M

Slightly volatile

Deferred Long Term Liabilities

464.5 K

312.3 K

481.6 K

Pretty Stable

Common Stock Total Equity

26.9 K

28.8 K

24.6 K

Slightly volatile

Capital Surpluse

552.3 M

582.7 M

507.4 M

Slightly volatile

Deferred Long Term Asset Charges

277.6 K

312.3 K

340.5 K

Slightly volatile

Neuropace Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Interest Income

1.5 M

3 M

768.2 K

Slightly volatile

Depreciation And Amortization

1.4 M

1.8 M

783.4 K

Slightly volatile

Interest Expense

7.1 M

8.8 M

9.1 M

Slightly volatile

Selling General Administrative

47.6 M

57.1 M

36.2 M

Slightly volatile

Total Revenue

57.6 M

79.9 M

44 M

Slightly volatile

Gross Profit

42.1 M

59.1 M

31.9 M

Slightly volatile

Other Operating Expenses

84.8 M

101.6 M

67.4 M

Slightly volatile

Research Development

21.7 M

23.7 M

19.1 M

Slightly volatile

Cost Of Revenue

15.4 M

20.8 M

12.1 M

Slightly volatile

Total Operating Expenses

69.4 M

80.8 M

55.3 M

Slightly volatile

Reconciled Depreciation

1.4 M

1.8 M

783.4 K

Slightly volatile

Income Tax Expense

1.2 M

1.3 M

8.2 M

Slightly volatile

Neuropace Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

6.5 M

10.3 M

3.4 M

Slightly volatile

Begin Period Cash Flow

14.5 M

18.2 M

8.2 M

Slightly volatile

Depreciation

1.4 M

1.8 M

783.4 K

Slightly volatile

Other Non Cash Items

3.3 M

2.6 M

3.1 M

Very volatile

Capital Expenditures

266.1 K

306 K

404.6 K

Slightly volatile

Total Cash From Financing Activities

4.1 M

4.3 M

24.3 M

Very volatile

End Period Cash Flow

16.3 M

13.6 M

8.9 M

Slightly volatile

Change To Netincome

6.5 M

12.5 M

4.5 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

5.25

4.0788

6.335

Slightly volatile

Days Sales Outstanding

69.4

58.7017

61.4116

Slightly volatile

Stock Based Compensation To Revenue

0.08

0.1287

0.066

Slightly volatile

Capex To Depreciation

0.16

0.173

0.8284

Slightly volatile

EV To Sales

6.33

4.8286

7.6625

Slightly volatile

Inventory Turnover

1.18

1.556

1.3747

Slightly volatile

Days Of Inventory On Hand

274

235

265

Slightly volatile

Payables Turnover

9.56

7.0484

10.4023

Slightly volatile

Research And Ddevelopement To Revenue

0.44

0.296

0.4543

Slightly volatile

Capex To Revenue

0.0036

0.0038

0.01

Slightly volatile

Cash Per Share

2.15

1.8112

1.4013

Slightly volatile

Days Payables Outstanding

35.62

51.7847

36.5698

Slightly volatile

Income Quality

0.81

0.6613

0.7983

Slightly volatile

Current Ratio

5.36

5.3668

3.0003

Slightly volatile

Receivables Turnover

4.67

6.2179

5.9377

Slightly volatile

Capex Per Share

0.0193

0.0105

0.0315

Slightly volatile

Revenue Per Share

2.94

2.7434

3.0572

Slightly volatile

Interest Debt Per Share

4.36

2.82

5.4182

Slightly volatile

Debt To Assets

1.17

0.7749

2.1448

Slightly volatile

Operating Cycle

343

293

326

Slightly volatile

Days Of Payables Outstanding

35.62

51.7847

36.5698

Slightly volatile

Ebt Per Ebit

1.53

1.2524

1.3834

Very volatile

Long Term Debt To Capitalization

0.83

0.8814

1.0025

Slightly volatile

Quick Ratio

4.82

4.4839

2.6496

Slightly volatile

Cash Ratio

1.36

0.8861

0.5827

Slightly volatile

Cash Conversion Cycle

294

241

289

Slightly volatile

Days Of Inventory Outstanding

274

235

265

Slightly volatile

Days Of Sales Outstanding

69.4

58.7017

61.4116

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

0.81

1.017

1.0036

Slightly volatile

Fixed Asset Turnover

5.89

6.1967

39.4215

Slightly volatile

Debt Ratio

1.17

0.7749

2.1448

Slightly volatile

Price Sales Ratio

5.25

4.0788

6.335

Slightly volatile

Asset Turnover

0.86

0.8443

1.3319

Slightly volatile

Gross Profit Margin

0.58

0.7394

0.7127

Pretty Stable

Neuropace Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

190.6 M

325.9 M

257.2 M

Slightly volatile

Enterprise Value

229.7 M

385.8 M

310.9 M

Slightly volatile

Neuropace Fundamental Market Drivers

Neuropace Upcoming Events

	7th of March 2024 Upcoming Quarterly Report	View
	2nd of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	7th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Neuropace Financial Statements

Neuropace stakeholders use historical fundamental indicators, such as Neuropace's revenue or net income, to determine how well the company is positioned to perform in the future. Although Neuropace investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neuropace's assets and liabilities are reflected in the revenues and expenses on Neuropace's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neuropace. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Current Deferred Revenue	555 K	527.2 K
Total Revenue	79.9 M	57.6 M
Cost Of Revenue	20.8 M	15.4 M
Stock Based Compensation To Revenue	0.13	0.08
Research And Ddevelopement To Revenue	0.30	0.44
Revenue Per Share	2.74	2.94
Ebit Per Revenue	(0.27)	(0.28)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

DD	Dupont De Nemours
CRDO	Credo Technology Group
GOOG	Alphabet Inc Class C

When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:

How To Invest In Neuropace

Details

Is Neuropace Stock a good investment?

Details

What is Neuropace's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of Neuropace Correlation against competitors.

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.

You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.75)

Revenue Per Share

2.978

Quarterly Revenue Growth

0.299

Return On Assets

(0.11)

Return On Equity

(1.69)

The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Neuropace Financial Statements From 2010 to 2026

Neuropace Total Revenue

57.59 Million

Neuropace Balance Sheet

Neuropace Income Statement

Neuropace Cash Flow Statement

Financial Ratios

Neuropace Valuation Data

Neuropace Fundamental Market Drivers

Neuropace Upcoming Events

About Neuropace Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY